文献速递骨质疏松与代谢性骨病

唑来膦酸序贯治疗预防既往接受奥达卡替治疗的绝经后骨质疏松症女性的骨丢失

Treatment with zoledronic acid subsequent to odanacatib prevents bone loss in postmenopausal women with osteoporosis.
PubMed 文献 · Osteoporos Int · 2019-01-17

研究纳入67例绝经后骨质疏松症女性,其中39例曾接受奥达卡替50mg每周一次治疗7年,28例曾接受安慰剂5年后奥达卡替2年,均给予唑来膦酸5mg治疗并随访12个月。结果显示腰椎骨密度较基线增加2.8±0.9%(p<0.01),全髋和股骨颈骨密度无显著变化,骨转换标志物维持在绝经前参考范围内。结论认为唑来膦酸5mg可维持骨转换标志物于绝经前范围并预防既往接受奥达卡替治疗女性的骨丢失。

要点

  • 唑来膦酸5mg使腰椎骨密度较基线增加2.8±0.9%(p<0.01),全髋和股骨颈无显著变化。
  • 唑来膦酸后3至12个月骨转换标志物升高,但12个月时仍处于绝经前参考范围。
  • 既往奥达卡替7年组与安慰剂5年+奥达卡替2年组之间各部位骨密度变化无差异(p≥0.20)。

核心结论

  • 唑来膦酸5mg治疗可维持骨转换标志物在绝经前范围,并预防既往接受奥达卡替治疗的绝经后骨质疏松症女性的骨丢失。

研究设计与样本

  • 研究纳入67例绝经后女性,给予唑来膦酸5mg治疗并随访12个月;其中39例曾接受奥达卡替50mg每周一次治疗7年,28例曾接受安慰剂5年后再接受奥达卡替2年。
  • 在唑来膦酸治疗后3、6、12个月测量骨转换标志物,并在唑来膦酸治疗时及12个月后进行脊柱和髋部双能X线吸收测定(DXA)。

主要发现

  • 整个研究人群中,腰椎骨密度从基线至12个月增加2.8±0.9%(均值±标准误)(p<0.01)。
  • 全髋骨密度(p=0.17)和股骨颈骨密度(p=0.39)无显著变化。
  • 两组间从基线至12个月各部位骨密度变化均无差异(所有p≥0.20)。
  • 唑来膦酸后3至12个月,CTX升高107±9%(p<0.001),PINP升高102±16%(p<0.001),骨钙素升高32±6%(p=0.001),BSAP升高79±37%(p=0.001)。
  • 12个月时骨转换标志物仍处于绝经前参考范围内;唑来膦酸后一年内S-25-羟基维生素D升高(p=0.059),PTH降低(p=0.007),eGFR降低(p=0.014)。

关键数值与推荐

  • 唑来膦酸5mg单次给药,随访12个月。
  • 奥达卡替50mg每周一次,既往治疗7年或安慰剂5年后奥达卡替2年。

临床怎么用

  • 原文未据此给出推荐。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

UNLABELLED: Treatment with zoledronic acid 5 mg maintained bone turnover markers in the premenopausal range, increased lumbar spine bone mineral density, and maintained hip bone mineral density in women previously treated with odanacatib 50 mg weekly. INTRODUCTION: The development of odanacatib (ODN), a cathepsin K inhibitor, for treatment of osteoporosis was discontinued due to an increased risk of cardiovascular events. As the treatment is considered reversible, participants from the LOFT trial in Aarhus, Denmark, were offered treatment with zoledronic acid (ZOL). METHODS: Sixty-seven postmenopausal women were treated with ZOL 5 mg and followed for 12 months. Of these, 39 had received ODN for 7 years and 28 had received placebo for 5 years and ODN for 2 years. Bone turnover markers (BTM) were measured 3, 6, and 12 months after ZOL, and DXA of spine and hip were performed at time of ZOL treatment and after 12 months. RESULTS: Within the entire study population, BMD at the lumbar spine increased by 2.8 ± 0.9% (mean ± SEM) (p < 0.01) from baseline to month 12. There was no significant change in BMD at the total hip (p = 0.17) or femoral neck (p = 0.39). There was no difference in the changes in BMD from baseline to 12 months between the two groups at any site (p ≥ 0.20 for all). CTX increased by 107 ± 9% (p < 0.001), PINP by 102 ± 16% (p < 0.001), osteocalcin by 32 ± 6% (p = 0.001) and BSAP by 79 ± 37% (p = 0.001) between 3 and 12 months after ZOL. At month 12, BTM were still within the premenopausal reference range. S-25-hydroxyvitamin D increased (p = 0.059), while PTH (p = 0.007) and eGFR (p = 0.014) decreased during the year following ZOL administration. CONCLUSION: Treatment with ZOL 5 mg maintained BTMs in the premenopausal range and prevented bone loss in women previously treated with ODN.

来源:Osteoporos Int,查看原文。版权归原作者所有。

引用

  1. Koldkjær Sølling AS, Harsløf T, Langdahl B, et al. Treatment with zoledronic acid subsequent to odanacatib prevents bone loss in postmenopausal women with osteoporosis. Osteoporos Int. 2019. PMID: 30656367. doi:10.1007/s00198-018-04833-3

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。